AstraZeneca Pharma will exit manufacturing at its only plant based in Bangalore, as part of a “global strategic review’’. The company with revenues of over Rs 1000 crore, feels that it can derive more value for its shareholders by transferring core manufacturing to a contract manufacturer. As a part of AstraZeneca’s ongoing strategic review of its global manufacturing and supply network, the company intends to exit the manufacturing site in Bangalore, in due course, it said in a stock exchange filing.
Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News